The highly neglected burden of resistant hypertension in Africa: a systematic review and meta-analysis

Jobert Richie N Nansseu, Jean Jacques N Noubiap, Michel K Mengnjo, Leopold Ndemnge Aminde, Mickael Essouma, Ahmadou M Jingi, Jean Joel R Bigna, Jobert Richie N Nansseu, Jean Jacques N Noubiap, Michel K Mengnjo, Leopold Ndemnge Aminde, Mickael Essouma, Ahmadou M Jingi, Jean Joel R Bigna

Abstract

Objective: The hypertension epidemic in Africa collectively with very low rates of blood pressure control may predict an incremented prevalence of resistant hypertension (RH) across the continent. The aim of this study was to determine the prevalence of RH and associated risk factors in Africa.

Data sources: We conducted a comprehensive search of electronic databases (PubMed, EMBASE, Africa Wide Information and Africa Index Medicus) completed by manual search of articles, regardless of language or publication date.

Methods: We included studies which have reported the prevalence and/or risk factors for RH in Africa from inception to 19 May 2016. Forest plots were drawn to visualise the combined prevalence of RH and extent of statistical heterogeneity between studies.

Results: Out of 259 retrieved studies, only 5 from Cameroon, Nigeria, Burkina Faso, Lesotho and Algeria with a total population of 4 068 patients were finally included in this review. There was no study from the Eastern part of Africa. Though the definition of RH was not similar across studies, its prevalence was respectively 11.7%, 4.9%, 14.6%, 14.3% and 19.0%, with an overall pooled prevalence of 12.1% (95% CI 8.0% to 17.7%). Potential risk factors were: non-compliance to treatment, ageing, male sex, dyslipidaemia, metabolic syndrome, previous cardiovascular events, physical inactivity and stress, but not excessive salt intake, alcohol and coffee ingestions. Moreover, diabetes, smoking, obesity and renal insufficiency yielded discrepant results.

Conclusions: There is a huge dearth of research on the epidemiology of RH in Africa. Thereby, an extensive study of RH prevalence and risk factors is still largely warranted to curtail the high and continuously increasing burden of hypertension across Africa.

Keywords: Africa; prevalence; resistant hypertension; risk factors; systematic review.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Process of identification and selection of studies for inclusion in the review (PRISMA flow diagram).
Figure 2
Figure 2
Forest plot of random-effects meta-analysis showing pooled prevalence of resistant hypertension.
Figure 3
Figure 3
Funnel plot showing no evidence of publication bias across studies.

References

    1. Forouzanfar MH, Alexander L, Anderson HR et al. . GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:2287–323. 10.1016/S0140-6736(15)00128-2
    1. World Health Organization. Global status report on non communicable diseases 2014: “attaining the nine global noncommunicable diseases targets; a shared responsibility” Geneva: World Health Organization, 2014.
    1. Ataklte F, Erqou S, Kaptoge S et al. . Burden of undiagnosed hypertension in sub-Saharan Africa: a systematic review and meta-analysis. Hypertension 2015;65:291–8. 10.1161/HYPERTENSIONAHA.114.04394
    1. Chow CK, Teo KK, Rangarajan S et al. . Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–68. 10.1001/jama.2013.184182
    1. Dzudie A, Kengne AP, Muna WF et al. . Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study. BMJ Open 2012;2:pii:e001217 10.1136/bmjopen-2012-001217
    1. Lloyd-Sherlock P, Beard J, Minicuci N et al. . Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol 2014;43:116–28. 10.1093/ije/dyt215
    1. Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a systematic review. Hypertension 2007;50:1012–18. 10.1161/HYPERTENSIONAHA.107.093336
    1. James PA, Oparil S, Carter BL et al. . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20. 10.1001/jama.2013.284427
    1. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014;28:463–8. 10.1038/jhh.2013.140
    1. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens 2015;28:355–61. 10.1093/ajh/hpu151
    1. Lotufo PA, Pereira AC, Vasconcellos PS et al. . Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens (Greenwich) 2015;17:74–80. 10.1111/jch.12433
    1. Boswell L, Pascual J, Oliveras A. Resistant hypertension: do all definitions describe the same patients? J Hum Hypertens 2015;29:530–4. 10.1038/jhh.2014.128
    1. Calhoun DA, Nishizaka MK, Zaman MA et al. . Hyperaldosteronism among black and White subjects with resistant hypertension. Hypertension 2002;40:892–6. 10.1161/01.HYP.0000040261.30455.B6
    1. Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol 2014;34:483–91. 10.1016/j.semnephrol.2014.08.001
    1. Yaméogo NV, Samadoulougou AK, Kagambèga LJ et al. . [Epidemiological characteristics and clinical features of black African subject's resistant hypertension]. Ann Cardiol Angeiol (Paris) 2014;63:83–8. 10.1016/j.ancard.2014.01.002
    1. Myat A, Redwood SR, Qureshi AC et al. . Resistant hypertension. BMJ 2012;345:e7473 10.1136/bmj.e7473
    1. Moher D, Liberati A, Tetzlaff J et al. . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9. 10.7326/0003-4819-151-4-200908180-00135
    1. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360–3.
    1. Wells G, Shea B, Peterson J et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2000. (accessed 31 Sep 2015).
    1. Cochran GW. The combination of estimates from different experiments. Biometrics 1954;10:101–29. 10.2307/3001666
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58. 10.1002/sim.1186
    1. Higgins JP, Thompson SG, Deeks JJ et al. . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60. 10.1136/bmj.327.7414.557
    1. Egger M, Davey Smith G, Schneider M et al. . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34. 10.1136/bmj.315.7109.629
    1. Gerber LM, Mann SJ, McDonald MV et al. . Diuretic use in black patients with uncontrolled hypertension. Am J Hypertens 2013;26:174–9. 10.1093/ajh/hps029
    1. Mutua EM, Gitonga MM, Mbuthia B et al. . Level of blood pressure control among hypertensive patients on follow-up in a regional referral hospital in Central Kenya. Pan Afr Med J 2014;18:278 10.11604/pamj.2014.18.278.4308
    1. Tanner RM, Calhoun DA, Bell EK et al. . Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013;8:1583–90. 10.2215/CJN.00550113
    1. Grigoryan L, Pavlik VN, Hyman DJ. Patterns of nonadherence to antihypertensive therapy in primary care. J Clin Hypertens (Greenwich) 2013;15:107–11. 10.1111/jch.12030
    1. Youmbissi TJ, Meli J, Kinkela MN et al. . Resistant hypertension in Yaounde. West Afr J Med 1994;13:175–8.
    1. Salako BL, Ayodele OE. Observed factors responsible for resistant hypertension in a teaching hospital setting. Afr J Med Med Sci 2003;32:151–4.
    1. Thinyane KH, Mothebe T, Sooro M et al. . An observational study of hypertension treatment and patient outcomes in a primary care setting. Pan Afr Med J 2015;20:424 10.11604/pamj.2015.20.424.5040
    1. Bachir Cherif A, Taleb A, Temmar M et al. . PP.40.21. Prevalence and causes of resistant hypertension in specialized consultation in the area of Blida (Algeria) . J Hypertens 2015;33(e-Supplement 1):e498.
    1. Hameed MA, Tebbit L, Jacques N et al. . Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens 2016;30:83–9. 10.1038/jhh.2015.38
    1. Jingi AM, Noubiap JJ, Ewane Onana A et al. . Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon. PLoS ONE 2014;9:e111812 10.1371/journal.pone.0111812
    1. Calhoun DA, Jones D, Textor S et al. . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403–19. 10.1161/HYPERTENSIONAHA.108.189141
    1. Williams B, MacDonald TM, Morant S et al. . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–68. 10.1016/S0140-6736(15)00257-3

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi